Update on vaccine development for renal cell cancer

Chi, Nina; Maranchie, Jodi K.; Appleman, Leonard Joseph; Storkus, Walter J.

doi:10.2147/rru.s7242

Cited by 4 publications

(1 citation statement)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this effect has been demonstrated to be transient, as prolonged anti-angiogenic treatments finally lead to vasculature rarefaction ( 110 ). Combinations between anti-angiogenic therapy and anti-tumoral vaccination are now in clinical development ( 111 ) and have already shown promising results in preclinical models ( 8 , 112 , 113 ). A stronger effect of vaccination when associated with sunitinib in a mouse model has been observed, with an increase of CD8+ T-cell infiltration, a decrease in Treg and MDSC infiltration, and a slower tumor growth ( 113 ).…”

Section: Reversal Of Endothelial Barrier: Clinical Applicationsmentioning

confidence: 99%

Control of the Adaptive Immune Response by Tumor Vasculature

et al. 2014

View full text Add to dashboard Cite

The endothelium is nowadays described as an entire organ that regulates various processes: vascular tone, coagulation, inflammation, and immune cell trafficking, depending on the vascular site and its specific microenvironment as well as on endothelial cell-intrinsic mechanisms like epigenetic changes. In this review, we will focus on the control of the adaptive immune response by the tumor vasculature. In physiological conditions, the endothelium acts as a barrier regulating cell trafficking by specific expression of adhesion molecules enabling adhesion of immune cells on the vessel, and subsequent extravasation. This process is also dependent on chemokine and integrin expression, and on the type of junctions defining the permeability of the endothelium. Endothelial cells can also regulate immune cell activation. In fact, the endothelial layer can constitute immunological synapses due to its close interactions with immune cells, and the delivery of co-stimulatory or co-inhibitory signals. In tumor conditions, the vasculature is characterized by an abnormal vessel structure and permeability, and by a specific phenotype of endothelial cells. All these abnormalities lead to a modulation of intra-tumoral immune responses and contribute to the development of intra-tumoral immunosuppression, which is a major mechanism for promoting the development, progression, and treatment resistance of tumors. The in-depth analysis of these various abnormalities will help defining novel targets for the development of anti-tumoral treatments. Furthermore, eventual changes of the endothelial cell phenotype identified by plasma biomarkers could secondarily be selected to monitor treatment efficacy.

show abstract

Section: Reversal Of Endothelial Barrier: Clinical Applicationsmentioning

confidence: 99%

Control of the Adaptive Immune Response by Tumor Vasculature

et al. 2014

View full text Add to dashboard Cite

show abstract

Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium

Russell¹,

Gorgulho²,

Allen³

et al. 2019

Cancer J

View full text Add to dashboard Cite

The clear cell subtype of kidney cancer encompasses most renal cell carcinoma cases and is associated with the loss of von Hippel-Lindau gene function or expression. Subsequent loss or mutation of the other allele influences cellular stress responses involving nutrient and hypoxia sensing. Autophagy is an important regulatory process promoting the disposal of unnecessary or degraded cellular components, tightly linked to almost all cellular processes. Organelles and proteins that become damaged or that are no longer needed in the cell are sequestered and digested in autophagosomes upon fusing with lysosomes, or alternatively, released via vesicular exocytosis. Tumor development tends to disrupt the regulation of the balance between this process and apoptosis, permitting prolonged cell survival and increased replication. Completed trials of autophagic inhibitors using hydroxychloroquine in combination with other anticancer agents including rapalogues and high-dose interleukin 2 have now been reported. The complex nature of autophagy and the unique biology of clear cell renal cell carcinoma warrant further understanding to better develop the next generation of relevant anticancer agents.

show abstract

Specific immunotherapy in renal cancer: a systematic review

Hirbod-Mobarakeh

Gordan

Zahiri

et al. 2016

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background: Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC. The aim of this systematic review was to assess the clinical efficacy of various approaches of specific immunotherapy in patients with RCC. Methods: We searched Medline, Scopus, CENTRAL, TRIP, DART, OpenGrey and ProQuest without any language filter through to 9 October 2015. One author reviewed search results for irrelevant and duplicate studies and two other authors independently extracted data from the studies. We collated study findings and calculated a weighted treatment effect across studies using Review Manager (version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration). Results: We identified 14 controlled studies with 4013 RCC patients after excluding irrelevant and duplicate studies from 11,319 references retrieved from a literature search. Overall, five autologous tumor cell vaccines, one peptide-based vaccine, one virus-based vaccine and one dendritic cell (DC)-based vaccine were studied in nine controlled studies of active specific immunotherapies. A total of three passive immunotherapies including autologous cytokineinduced killer (CIK) cells, auto lymphocyte therapy (ALT) and autologous lymphokine-activated killer (LAK) cells were studied in four controlled studies. The clinical efficacy of tumor lysatepulsed DCs, with CIK cells was studied in one controlled trial concurrently. The overall quality of studies was fair. Meta-analysis of seven studies showed that patients undergoing specific immunotherapy had significantly higher overall survival (OS) than those in the control group [hazard ratio (HR) = 0.72; 95% confidence interval (CI) = 0.58-0.89, p = 0.003]. In addition, a meta-analysis of four studies showed that there was a significant difference in progressionfree survival (PFS) between patients undergoing specific immunotherapy and patients in control groups (HR = 0.86; 95% CI = 0.73-1, p = 0.05). Conclusions: Results of this systematic review suggest that some specific immunotherapies such as Reniale, ACHN-IL-2, Newcastle disease virus (NDV) virus-infected autologous tumor cells, ALT and CIK treatment could be beneficiary for the treatment of patients with RCC.

show abstract

Update on vaccine development for renal cell cancer

Cited by 4 publications

References 227 publications

Control of the Adaptive Immune Response by Tumor Vasculature

Control of the Adaptive Immune Response by Tumor Vasculature

Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium

Specific immunotherapy in renal cancer: a systematic review

Contact Info

Product

Resources

About